Oryzon Genomics S.A
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system) disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, … Read more
Oryzon Genomics S.A (ORYZF) - Total Liabilities
Latest total liabilities as of September 2025: $34.06 Million USD
Based on the latest financial reports, Oryzon Genomics S.A (ORYZF) has total liabilities worth $34.06 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Oryzon Genomics S.A - Total Liabilities Trend (2013–2024)
This chart illustrates how Oryzon Genomics S.A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Oryzon Genomics S.A Competitors by Total Liabilities
The table below lists competitors of Oryzon Genomics S.A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Meorient
SHE:300795
|
China | CN¥312.07 Million |
|
Padini Holdings Bhd
KLSE:7052
|
Malaysia | RM841.07 Million |
|
First Insurance Co Ltd
TW:2852
|
Taiwan | NT$9.24 Billion |
|
Solowin Holdings
NASDAQ:AXG
|
USA | $14.17 Million |
|
Prosperity Dielectrics Co Ltd
TWO:6173
|
Taiwan | NT$1.08 Billion |
|
Humble Group AB
ST:HUMBLE
|
Sweden | Skr3.89 Billion |
|
Pure Cycle Corporation
NASDAQ:PCYO
|
USA | $20.58 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Oryzon Genomics S.A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | N/A | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oryzon Genomics S.A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oryzon Genomics S.A (2013–2024)
The table below shows the annual total liabilities of Oryzon Genomics S.A from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $21.67 Million | -13.74% |
| 2023-12-31 | $25.13 Million | -19.28% |
| 2022-12-31 | $31.13 Million | +29.04% |
| 2021-12-31 | $24.12 Million | +32.72% |
| 2020-12-31 | $18.18 Million | -4.16% |
| 2019-12-31 | $18.97 Million | -15.05% |
| 2018-12-31 | $22.33 Million | -16.11% |
| 2017-12-31 | $26.61 Million | -1.49% |
| 2016-12-31 | $27.02 Million | +105.63% |
| 2015-12-31 | $13.14 Million | +8.00% |
| 2014-12-31 | $12.16 Million | -13.32% |
| 2013-12-31 | $14.03 Million | -- |